Cargando…

Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration

OBJECTIVE: In Turkiye, the increased likelihood of survival of small premature babies has resulted in a higher incidence of retinopathy of prematurity (ROP), which causes severe visual impairment in childhood. Early diagnosis and timely and proper treatment of ROP can prevent vision loss. This paper...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Ozlem, Boga, Aysun, Hacioglu, Gulay Karakus, Sozen, Hatice Gulhan, Bilgin, Leyla Karadeniz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500235/
https://www.ncbi.nlm.nih.gov/pubmed/37719258
http://dx.doi.org/10.14744/nci.2022.22308
_version_ 1785105880067342336
author Sahin, Ozlem
Boga, Aysun
Hacioglu, Gulay Karakus
Sozen, Hatice Gulhan
Bilgin, Leyla Karadeniz
author_facet Sahin, Ozlem
Boga, Aysun
Hacioglu, Gulay Karakus
Sozen, Hatice Gulhan
Bilgin, Leyla Karadeniz
author_sort Sahin, Ozlem
collection PubMed
description OBJECTIVE: In Turkiye, the increased likelihood of survival of small premature babies has resulted in a higher incidence of retinopathy of prematurity (ROP), which causes severe visual impairment in childhood. Early diagnosis and timely and proper treatment of ROP can prevent vision loss. This paper discusses cases of ROP treated with bevacizumab. METHODS: Patients treated with bevacizumab for ROP were evaluated retrospectively. Systolic and diastolic blood pressure values were recorded 1 day before and 2 weeks after bevacizumab administration. The Bayley III test, hearing test, eye examination, and neurological evaluation were performed. RESULTS: The mean composite Bayley III test scores for cognition, language, motor, social-emotional, and adaptive domains in 10 patients who received bevacizumab for ROP were 75±10.8, 73.4±15.4, 71.2±10.2, 88±23.7, and 65.4±13.8, respectively. The mean values of the day before the injection and the values of the 14 days after the injection were compared, it was seen that there was a significant increase in systolic blood pressure values, especially at the end of 1(st) day and 1(st) week after the surgery. Neurological examination results were abnormal in 50% of the cases. Vision problems were detected in 40% of the cases. About 30% of the babies failed the hearing test. CONCLUSION: Caution needs attention in the care of neonates until further studies of the long-term benefits and effects of bevacizumab therapy are completed.
format Online
Article
Text
id pubmed-10500235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-105002352023-09-15 Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration Sahin, Ozlem Boga, Aysun Hacioglu, Gulay Karakus Sozen, Hatice Gulhan Bilgin, Leyla Karadeniz North Clin Istanb Original Article OBJECTIVE: In Turkiye, the increased likelihood of survival of small premature babies has resulted in a higher incidence of retinopathy of prematurity (ROP), which causes severe visual impairment in childhood. Early diagnosis and timely and proper treatment of ROP can prevent vision loss. This paper discusses cases of ROP treated with bevacizumab. METHODS: Patients treated with bevacizumab for ROP were evaluated retrospectively. Systolic and diastolic blood pressure values were recorded 1 day before and 2 weeks after bevacizumab administration. The Bayley III test, hearing test, eye examination, and neurological evaluation were performed. RESULTS: The mean composite Bayley III test scores for cognition, language, motor, social-emotional, and adaptive domains in 10 patients who received bevacizumab for ROP were 75±10.8, 73.4±15.4, 71.2±10.2, 88±23.7, and 65.4±13.8, respectively. The mean values of the day before the injection and the values of the 14 days after the injection were compared, it was seen that there was a significant increase in systolic blood pressure values, especially at the end of 1(st) day and 1(st) week after the surgery. Neurological examination results were abnormal in 50% of the cases. Vision problems were detected in 40% of the cases. About 30% of the babies failed the hearing test. CONCLUSION: Caution needs attention in the care of neonates until further studies of the long-term benefits and effects of bevacizumab therapy are completed. Kare Publishing 2023-08-07 /pmc/articles/PMC10500235/ /pubmed/37719258 http://dx.doi.org/10.14744/nci.2022.22308 Text en © Copyright 2023 by Istanbul Provincial Directorate of Health https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Original Article
Sahin, Ozlem
Boga, Aysun
Hacioglu, Gulay Karakus
Sozen, Hatice Gulhan
Bilgin, Leyla Karadeniz
Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title_full Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title_fullStr Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title_full_unstemmed Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title_short Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
title_sort evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500235/
https://www.ncbi.nlm.nih.gov/pubmed/37719258
http://dx.doi.org/10.14744/nci.2022.22308
work_keys_str_mv AT sahinozlem evaluationofbabieswithretinopathyofprematurityfollowingintravitrealbevacizumabadministration
AT bogaaysun evaluationofbabieswithretinopathyofprematurityfollowingintravitrealbevacizumabadministration
AT hacioglugulaykarakus evaluationofbabieswithretinopathyofprematurityfollowingintravitrealbevacizumabadministration
AT sozenhaticegulhan evaluationofbabieswithretinopathyofprematurityfollowingintravitrealbevacizumabadministration
AT bilginleylakaradeniz evaluationofbabieswithretinopathyofprematurityfollowingintravitrealbevacizumabadministration